Nick Norwitz

This has been my lived experience, despite the fact that it's not a quote, evidence-based approach. So a lot of what I've been thinking about with respect to metabolic health- The absence of evidence is not the evidence of absence.

But I'd heard that saying before starting medical school, but it really didn't sink in until I started to think about our current biomedical infrastructure business models around health. and why certain interventions would or would not be explored.

But I'd heard that saying before starting medical school, but it really didn't sink in until I started to think about our current biomedical infrastructure business models around health. and why certain interventions would or would not be explored.

But I'd heard that saying before starting medical school, but it really didn't sink in until I started to think about our current biomedical infrastructure business models around health. and why certain interventions would or would not be explored.

Right, so it hasn't been properly explored and which makes it, to me, the low-hanging fruit for treating all these chronic metabolic diseases, which we have been poorly equipped to address. Cardiovascular disease, inflammatory bowel disease, obesity, diabetes.

Right, so it hasn't been properly explored and which makes it, to me, the low-hanging fruit for treating all these chronic metabolic diseases, which we have been poorly equipped to address. Cardiovascular disease, inflammatory bowel disease, obesity, diabetes.

Right, so it hasn't been properly explored and which makes it, to me, the low-hanging fruit for treating all these chronic metabolic diseases, which we have been poorly equipped to address. Cardiovascular disease, inflammatory bowel disease, obesity, diabetes.

Mental health issues as well.

Mental health issues as well.

Mental health issues as well.

Is it Shabani Sethi? Yeah. Yeah.

Is it Shabani Sethi? Yeah. Yeah.

Is it Shabani Sethi? Yeah. Yeah.

I've done a little bit of work with her, Chris Palmer, Suzuki Group, Metabolic Mind. The universe of things that we could treat with rigorous metabolic therapies is truly impressive. But in order to make that standard of care, we need to grapple with the fact that they're not by conventional metrics currently, quote, evidence-based.

I've done a little bit of work with her, Chris Palmer, Suzuki Group, Metabolic Mind. The universe of things that we could treat with rigorous metabolic therapies is truly impressive. But in order to make that standard of care, we need to grapple with the fact that they're not by conventional metrics currently, quote, evidence-based.

I've done a little bit of work with her, Chris Palmer, Suzuki Group, Metabolic Mind. The universe of things that we could treat with rigorous metabolic therapies is truly impressive. But in order to make that standard of care, we need to grapple with the fact that they're not by conventional metrics currently, quote, evidence-based.

because there isn't the research and funding infrastructure to do these trials with the same degree of, quote, rigor as pharmaceuticals. Because again, the business model isn't as clear. It's very clear if you produce a pill and it treats a disease, you can sell that drug and make a massive profit, even if The drug doesn't help most people.

because there isn't the research and funding infrastructure to do these trials with the same degree of, quote, rigor as pharmaceuticals. Because again, the business model isn't as clear. It's very clear if you produce a pill and it treats a disease, you can sell that drug and make a massive profit, even if The drug doesn't help most people.

because there isn't the research and funding infrastructure to do these trials with the same degree of, quote, rigor as pharmaceuticals. Because again, the business model isn't as clear. It's very clear if you produce a pill and it treats a disease, you can sell that drug and make a massive profit, even if The drug doesn't help most people.

You can get a statistically significant result in a trial that you publish in the New England Journal, and it can still help only a minority of people.